Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Vyxeos“
Suchtreffer
Begriffe & Kennungen
Vyxeos liposomal (previously Vyxeos)
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.1 Therapeutic indications · 1
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.3 Contraindications · 1
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.3 · History of serious hypersensitivity to the active substances or to any of the excipients listed in section 6.1
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.5 · Cardiotoxic agents Concurrent use of cardiotoxic agents may increase the risk of cardiotoxicity. Use of Vyxeos
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.5 · Hepatotoxic agents Hepatotoxic medicinal products may impair liver function and increase the toxicity. Since d
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.5 · No interaction studies have been performed with Vyxeos liposomal. The delivery of daunorubicin and cytarabine
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 Undesirable effects · 1
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 · 10 those seen in adults (acknowledging limitations of cross study comparisons) included rash maculo- papular (
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 · 8 System organ class ADRs/Frequency (%) Grade 3-5 ADRs/Frequency (%) Nervous system disorders Very common Comm
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 · 9 System organ class ADRs/Frequency (%) Grade 3-5 ADRs/Frequency (%) General disorders and Very common Very co
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 · Cardiotoxicity Cardiotoxicities were seen in Vyxeos liposomal clinical studies. The most frequently reported s
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 · Common Common Thrombocytopenia (4.5) Thrombocytopenia (3.7) Neutropenia (3.7) Neutropenia (3.5) Anaemia (3.2)
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 · Common Night sweats (8.3) Alopecia (3.2)
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 · De Novo AML The safety of Vyxeos liposomal in combination with gemtuzumab ozogamicin was studied in 361 paedia
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 · Description of selected adverse reactions
Eintrag öffnenVyxeos liposomal (previously Vyxeos) · 4.8 · Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to < 1/100); rar
Eintrag öffnen